Investor FAQ
Arcturus’s investor relations team is happy to answer any shareholder questions. You may contact Arcturus’s investor relations by phone at 858-900-2682 or by email at IR@ArcturusRx.com.
Information can be accessed directly through the Company’s website (https://arcturusrx.com). Annual reports on Form 20-F, periodic reports on Form 6-K, and other filings with the SEC can be accessed directly through the Arcturus website or through the Securities and Exchange Commission’s website at http://www.sec.gov.
10285 Science Center Drive,
San Diego, CA 92121
Arcturus ordinary shares trade under the symbol “ARCT.”
Shares of Arcturus trade on The NASDAQ Global Market.
The total number of shares outstanding for Arcturus can be found in Arcturus’s filings with the SEC at http://www.sec.gov and are also available at https://arcturusrx.com.
Arcturus’s fiscal year end is December 31st.
No, Arcturus does not offer a Direct Stock Purchase Plan at this time.
Arcturus does not currently intend to declare distributions on its shares in the foreseeable future.
Continental Stock Transfer & Trust Company
Mail/overnight address:
17 Battery Place, 8th Floor
New York, NY 10004
Phone: +1 800.509.5586
Arcturus’s independent auditor is Ernst & Young LLP.
Arcturus’s investor relations team is happy to answer any shareholder questions. You may contact Arcturus’s investor relations by phone at 858-900-2682 or by email at IR@ArcturusRx.com.